Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · Real-Time Price · USD
1.170
-0.060 (-4.88%)
At close: Apr 1, 2025, 4:00 PM
1.200
+0.030 (2.56%)
After-hours: Apr 1, 2025, 4:29 PM EDT
Iterum Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Iterum Therapeutics stock has a target of 5.00, which predicts an increase of 327.35% from the current stock price of 1.17.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 10, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Iterum Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +327.35% | Sep 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +327.35% | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +412.82% | Jun 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +412.82% | May 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +412.82% | May 14, 2024 |
Financial Forecast
Revenue This Year
11.90M
Revenue Next Year
29.76M
from 11.90M
Increased by 150.10%
EPS This Year
-0.65
from -1.26
EPS Next Year
-0.52
from -0.65
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.2M | 30.6M | 75.4M | ||
| Avg | 11.9M | 29.8M | 73.3M | ||
| Low | 11.4M | 28.6M | 70.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 157.5% | 153.5% | ||
| Avg | - | 150.1% | 146.2% | ||
| Low | - | 140.3% | 136.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.67 | -0.54 | 0.07 |
| Avg | -0.65 | -0.52 | 0.07 |
| Low | -0.63 | -0.50 | 0.07 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.